New Report Exposes Extreme Profit Retained from 340B Program by Covered Entities, Particularly for Oncology Medicines

Today, the Alliance for Integrity and Reform of 340B (AIR340B) released a new report by Health Capital Group that uncovered significant growth in sales within the 340B Drug Pricing Program, including a near 200% increase in hospital participation in the program over the last decade. The question that remains is whether this growth has benefited patients.

Scroll to Top